![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Departments of Medicine (K.M., C.J.L.), Pathology (C.N.M., C.J.L.), and Comparative Medicine (C.N.M.), The Johns Hopkins University School of Medicine, Baltimore, Maryland
Abstract
N-Ethyl-maleimide-sensitive factor (NSF) plays a critical role in the regulation of exocytosis. NSF regulates exocytosis by interacting with a complex containing soluble NSF attachment protein receptor (SNARE) molecules, hydrolyzing ATP, and disassembling the SNARE complex. We hypothesized that peptide inhibitors of NSF would decrease exocytosis. We now report the development of a novel set of peptides that block exocytosis by inhibiting NSF activity. These NSF inhibitors are fusion polypeptides composed of an 11 amino acid human immunodeficiency virus transactivating regulatory protein (TAT) domain fused to a 22 amino acid NSF domain. These TAT-NSF fusion polypeptides cross endothelial cell membranes, inhibit NSF hydrolysis of ATP, decrease NSF disassembly of SNARE molecules, and block exocytosis of von Willebrand factor. Control peptides have no effect on exocytosis. TAT-NSF inhibitors administered to mice prolong the bleeding time. Blood concentrations of these TAT-NSF peptides rapidly decrease within 5 min after injection and then remain constant from 10 to 60 min after injection. These TAT-NSF compounds may be useful in the treatment of a variety of diseases in which exocytosis plays a prominent role, including myocardial infarction, stroke, thrombosis, and autoimmune disorders.
Address correspondence to: Dr. Charles J. Lowenstein, 950 Ross Building, 720 Rutland Avenue, The Johns Hopkins University School of Medicine, Baltimore, MD 21205. E-mail: clowenst{at}jhmi.edu
This article has been cited by other articles:
|
|
 |
|
  J. W. Calvert, S. Gundewar, M. Yamakuchi, P. C. Park, W. M. Baldwin III, D. J. Lefer, and C. J. Lowenstein Inhibition of N-Ethylmaleimide Sensitive Factor Protects Against Myocardial Ischemia/Reperfusion Injury Circ. Res., December 7, 2007; 101(12): 1247 - 1254. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Ramaraj, M. B. Forman, E. K. Jackson, C. J. Lowenstein, B. Ibanez, G. Cimmino, J. J. Badimon, P. G. Korantzopoulos, J. A. Goudevenos, D. M. Yellon, et al. Myocardial reperfusion injury. N. Engl. J. Med., December 6, 2007; 357(23): 2408 - 2408. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yamakuchi, N. C. Kirkiles-Smith, M. Ferlito, S. J. Cameron, C. Bao, K. Fox-Talbot, B. A. Wasowska, W. M. Baldwin III, J. S. Pober, and C. J. Lowenstein Antibody to human leukocyte antigen triggers endothelial exocytosis PNAS, January 23, 2007; 104(4): 1301 - 1306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. LoPachin and D. S. Barber Synaptic Cysteine Sulfhydryl Groups as Targets of Electrophilic Neurotoxicants Toxicol. Sci., December 1, 2006; 94(2): 240 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Yamakuchi, J. J.M. Greer, S. J. Cameron, K. Matsushita, C. N. Morrell, K. Talbot-Fox, W. M. Baldwin III, D. J. Lefer, and C. J. Lowenstein HMG-CoA Reductase Inhibitors Inhibit Endothelial Exocytosis and Decrease Myocardial Infarct Size Circ. Res., June 10, 2005; 96(11): 1185 - 1192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. E. Eiden Fusion Polypeptides That Inhibit Exocytosis: Fusing Aptamer and Cell-Penetrating Peptide Technologies and Pharmacologies Mol. Pharmacol., April 1, 2005; 67(4): 980 - 982. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
